Pharmahungary Group, an innovative preclinical and clinical R&D company, launches online version of miRNAtarget, www.mirnatarget.com. The new miRNA target-analysis service of Pharmahungary Group is able to analyze the targets of miRNAs from a network theoretical perspective and to predict the most probable mRNA targets of differentially expressed miRNAs
MiRNAtarget is a simple and powerful network theoretical approach to identify the most probable common targets of differentially expressed miRNAs relying on multiple miRNA-target interaction databases.
“MiRNAtarget has several advantages e.g. increased coverage of possible miRNA-target interactions compared to experimentally validated databases” said Peter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group, a group of innovative R&D companies. “MiRNAtarget offers a novel, unbiased approach for drug target identification by utilizing miRNA transcriptomics data and analysis based on network theory and bioinformatics approach.”
“MiRNAtarget is able to provide higher accuracy than currently available predicted miRNA-target interaction databases” said Bence Ágg, MD, Bioinformatics expert of Pharmahungary Group. “MiRNAtarget has been validated in two animal studies, manuscripts summarizing the results of the validation will be published soon in leading medical journals.”
The project was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program).
Pharmahungary Group is an innovative preclinical (nonclinical) and clinical R&D company providing contract research with strong scientific support and also offering early-stage novel technologies for out-licensing.
Pharmahungary launches online version, mirnatarget
